Furthermore, a study that developed a glycosylated polymeric siRNA nanomedicine known as Gal-NP@siRNA showed that systemic administration of 1 mg/kg of the glycosylated siRNA led to lower expression of the target gene and improvement of cognitive decline in the APP/PS1 mouse model of Alzheimer’s disease (Zhou et al., 2020). This evidence concerns the gene APP and Alzheimer disease.